Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice

PURPOSE: The antiplatelet prodrug clopidogrel is bioactivated by the polymorphic enzyme CYP2C19. Prospective clinical studies demonstrated an association between CYP2C19 loss of function (LoF) variants and an increased risk of thrombotic events under clopidogrel, but pharmacogenetic (PGx) testing is...

Descripción completa

Detalles Bibliográficos
Autores principales: Russmann, Stefan, Rahmany, Ali, Niedrig, David, Hatz, Karl-Dietrich, Ludin, Katja, Burden, Andrea M., Englberger, Lars, Backhaus, Roland, Serra, Andreas, Béchir, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Pharmacogenetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032605/
https://www.ncbi.nlm.nih.gov/pubmed/33242107
http://dx.doi.org/10.1007/s00228-020-03050-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032605/
https://www.ncbi.nlm.nih.gov/pubmed/33242107
http://dx.doi.org/10.1007/s00228-020-03050-4

Ejemplares similares